ResMed Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
ResMed Inc. (RMD) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of -$9.92 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2023-08-11
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2021-06-30 was -$5.07M.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2021-03-31 was -$4.67M, a 151.27% decline year-over-year.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-12-31 was $3.70M, a 30.79% increase year-over-year.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-09-30 was -$8.48M, a 427.26% decline year-over-year.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was -$9.92M, a 181.31% decline from fiscal 2022.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $12.20M.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2021 was -$14.52M, a 199.97% decline from fiscal 2020.
- ResMed Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2020 was $14.52M, a 3.25% decline from fiscal 2019.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$9.92M 10-K · filed 2023-08-11 | |||
| 2022-06-30 | $12.20M 10-K · filed 2023-08-11 | |||
| 2021-06-30 | -$5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-11 | -$9.74M derived: sum of 2 quarters · filed 2023-08-11 | -$6.04M derived: sum of 3 quarters · filed 2023-08-11 | -$14.52M 10-K · filed 2023-08-11 |
| 2021-03-31 | -$4.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-30 | -$966.00K derived: sum of 2 quarters · filed 2021-04-30 | -$9.44M 10-Q · filed 2021-04-30 | -$9.44M derived: sum of 4 quarters · filed 2022-08-12 |
| 2020-12-31 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-29 | -$4.78M 10-Q · filed 2021-01-29 | -$4.78M derived: sum of 3 quarters · filed 2022-08-12 | $4.32M derived: sum of 4 quarters · filed 2022-08-12 |
| 2020-09-30 | -$8.48M 10-Q · filed 2020-10-30 | -$8.48M derived: sum of 2 quarters · filed 2022-08-12 | $624.00K derived: sum of 3 quarters · filed 2022-08-12 | $3.45M derived: sum of 4 quarters · filed 2022-08-12 |
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-12 | $9.10M derived: sum of 2 quarters · filed 2022-08-12 | $11.93M derived: sum of 3 quarters · filed 2022-08-12 | $14.52M 10-K · filed 2022-08-12 |
| 2020-03-31 | $9.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-30 | $11.93M derived: sum of 2 quarters · filed 2021-04-30 | $14.52M 10-Q · filed 2021-04-30 | |
| 2019-12-31 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-29 | $5.42M 10-Q · filed 2021-01-29 | ||
| 2019-09-30 | $2.59M 10-Q · filed 2020-10-30 | |||
| 2019-06-30 | $15.01M 10-K · filed 2021-08-17 | |||
| 2018-06-30 | $11.59M 10-K · filed 2020-08-13 |